The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Prognostic value of pre-treatment health-related QoL indicators in AML: analysis from EORTC AML21
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy, comments on the prognostic value of baseline quality of life (QoL) data in patients with acute myeloid leukemia (AML) enrolled in the EORTC AML21 trial (NCT02172872). Dr Efficace notes that this finding has key implications for defining fitness in patients with AML, which is crucial in determining whether a patient can tolerate aggressive treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
